The Department of Justice's 2026 National Health Care Fraud Takedown, announced June 23, 2026, charged 455 defendants, including 90 doctors and other licensed medical professionals, in connection with more than $6.5 billion in alleged fraud, and telemedicine schemes again featured prominently among the charges. For telehealth providers, the pattern DOJ keeps prosecuting is narrow and repeats takedown after takedown: a marketing operation generates the lead, a prescriber signs an order with little or no clinical evaluation behind it, and a pharmacy or supplier bills Medicare, Medicaid, or TRICARE on the back end. A platform, prescriber, or pharmacy that fits any part of that pattern is now a viable federal target.
The DOJ's 2026 Health Care Fraud Takedown
The June 2026 takedown spanned 56 federal districts and 45 states and territories, with 50 state Medicaid Fraud Control Units participating, the most in DOJ history, and it produced the seizure of more than $182 million in cash, vehicles, and other assets. One case DOJ cited involved a fugitive apprehended in the Philippines tied to a previously charged $1.2 billion telemedicine fraud scheme, a reminder that telehealth is a standing DOJ enforcement priority rather than a single sweep. The 2025 takedown told the same story at a different scale: 49 of the 324 defendants charged that year were tied to more than $1.17 billion in fraudulent Medicare claims built on telemedicine and genetic-testing schemes, including a $46 million scheme in the Southern District of Florida built on telemarketing to Medicare beneficiaries.
Fee-Per-Order Prescriber Arrangements
Telehealth companies that pay a prescriber a fee tied to the volume of orders signed, rather than a fixed rate for time spent, sit squarely inside Anti-Kickback Statute exposure. A March 2026 judgment of more than $31 million against a Mississippi defendant illustrated the pattern: marketers identified patients, in that case retired military personnel near bases whose TRICARE coverage carried historically high reimbursement rates, and received a percentage of the pharmacy's net profits from reimbursed claims, while telehealth prescribers who lacked a preexisting relationship with the patient signed prescriptions without a meaningful clinical evaluation. Five co-defendants had already settled before the judgment. The same pattern, marketer-driven leads, compensation tied to volume or profit rather than time, and prescribers who never meaningfully evaluate the patient, recurs across nearly every telehealth-related False Claims Act and Anti-Kickback Statute case DOJ has brought since 2024.
Medical Necessity Documentation Is the Recurring Failure Point
Almost every telehealth fraud case DOJ has charged since the 2025 takedown turns on the same documentation gap: the record fails to show a licensed prescriber evaluated the patient before ordering the drug, device, or test billed. When a platform's workflow moves a lead to a signed order within minutes, the chart often lacks the history, exam findings, or clinical reasoning that would establish medical necessity if a Medicare or Medicaid auditor, or a grand jury, later reviews the file. HHS Office of Inspector General's Advisory Opinion 25-03, issued June 11, 2025, shows what a compliant structure looks like instead: OIG approved a telehealth staffing arrangement only because the fees were fixed in advance, unrelated to referral volume, and the clinical relationship behind each visit was real. For the billing-specific side of this exposure, see Telehealth Billing Audits: Modifiers, Originating Sites, and Time. Prescribers who also handle controlled substances face overlapping DEA scrutiny; see Prescribing Controlled Substances via Telehealth: The Current Rules.
The fact pattern DOJ keeps prosecuting is not exotic. Marketing generates the lead, a prescriber signs with no real evaluation, and a pharmacy or supplier bills the claim.
Why Early Legal Counsel Is Critical
It is critical that telehealth providers, prescribers, and platform operators promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry tied to marketing arrangements, prescriber compensation, or medical necessity documentation. Early legal intervention can protect the provider's rights, help ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance represents telehealth providers, prescribers, and platform operators facing DOJ healthcare fraud investigations, Anti-Kickback Statute and False Claims Act allegations, and Medicare or Medicaid audits tied to marketing arrangements and prescriber compensation structures. We review the underlying marketing agreements, prescriber fee arrangements, and clinical documentation to assess exposure before a matter escalates from an inquiry to an indictment, and we communicate with investigators and agents on the provider's behalf. If your telehealth practice or platform has received a subpoena, a civil investigative demand, or another government inquiry, contact us for a free, confidential consultation.
